Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
6
result(s) for
"Mullane, Frank"
Sort by:
Response Crime victims should not be excluded from the legal process: Consulting victims and their families would uphold justice and basic decency, says Frank Mullane
[Sara Payne] hasn't recommended that victims play a major part in deciding sentencing or that legal principles should be abandoned. She urged that the needs of those victims who never go to court (the overwhelming majority) are seen as \"just as important\"; that victims should be kept better informed, and sentencing should be made more understandable. These are simply fundamental decencies that the criminal justice system can surely not resist. In the six years since my sister and her son were murdered I have often heard of the distress caused to victims because they believed life meant life behind bars. [David Wilson] says he's not convinced that the criminal justice system is \"the best place for victims' needs to be addressed. I would have presumed that these were much better managed through, for example, the NHS - if counselling or health needs were paramount\". But Sara Payne made a similar point in her report - that the justice system should address the full impact of the crime on the victim and that \"in doing this we would open up the need for other statutory agencies from outside the criminal justice system to become involved\".
Newspaper Article
Comment & Debate: Lessons that can save lives: A litany of errors allowed my sister and her son to die at the hands of her husband
When my sister Julia Pemberton placed her trust in Thames Valley police, her fate was sealed. She told them that her estranged husband Alan had \"coldly and chillingly\" threatened to kill her and that she emphatically believed he would. This happened after Julia mentioned divorce, following years of abuse, and we repeatedly begged the police for help. But 14 months later, in November 2003, Alan shot his son, Will, and then killed Julia as she was making a desperate 999 call to the police. After Alan's initial death threats, Julia and I spent a whole weekend begging the police to intervene. The next day, a police officer recorded: \"I have not come across such a cruel act . . . I have flagged Julia's address . . . any incidents to and from the house are to be treated urgently. This does not happen for every person I talk to . . . I believe the perceived threat level to Julia has escalated.\" Several months later, the external locks of Julia's house were glued shut while she was away. The police failed to investigate despite us warning of continuing abuse. Alan Pemberton, the only suspect, was the subject of an injunction with power of arrest. After repeated requests the police promised to interview him. They never did. A few weeks later Alan posted more death threats through her letter box. Julia and I took them to the police, who again did nothing, except lose the evidence in the archives.
Newspaper Article
Lessons that can save lives
When my sister Julia Pemberton placed her trust in Thames Valley police, her fate was sealed. She told them that her...
Newspaper Article
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
The mRNA-1273 vaccine for coronavirus disease 2019 (COVID-19) demonstrated 93.2% efficacy in reduction of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the blinded portion of the Phase 3 Coronavirus Efficacy (COVE) trial. While mRNA-1273 demonstrated high efficacy in prevention of COVID-19, including severe disease, its effect on the viral dynamics of SARS-CoV-2 infections is not understood. Here, in exploratory analyses, we assessed the impact of mRNA-1273 vaccination in the ongoing COVE trial (number NCT04470427) on SARS-CoV-2 copy number and shedding, burden of disease and infection, and viral variants. Viral variants were sequenced in all COVID-19 and adjudicated COVID-19 cases (
n
= 832), from July 2020 in the blinded part A of the study to May 2021 of the open-label part B of the study, in which participants in the placebo arm started to receive the mRNA-1273 vaccine after US Food and Drug Administration emergency use authorization of mRNA-1273 in December 2020. mRNA-1273 vaccination significantly reduced SARS-CoV-2 viral copy number (95% confidence interval) by 100-fold on the day of diagnosis compared with placebo (4.1 (3.4–4.8) versus 6.2 (6.0–6.4) log
10
copies per ml). Median times to undetectable viral copies were 4 days for mRNA-1273 and 7 days for placebo. Vaccination also substantially reduced the burden of disease and infection scores. Vaccine efficacies (95% confidence interval) against SARS-CoV-2 variants circulating in the United States during the trial assessed in this post hoc analysis were 82.4% (40.4–94.8%) for variants Epsilon and Gamma and 81.2% (36.1–94.5%) for Epsilon. The detection of other, non-SARS-CoV-2, respiratory viruses during the trial was similar between groups. While additional study is needed, these data show that in SARS-CoV-2-infected individuals, vaccination reduced both the viral copy number and duration of detectable viral RNA, which may be markers for the risk of virus transmission.
The COVID-19 vaccine mRNA-1273 reduced SARS-CoV-2 copy number and duration of virus shedding, in addition to disease burden and infections, in exploratory analyses of breakthrough infections in the COVE trial.
Journal Article